Still waiting for a response from Titan...
Hi Todd,
I listened alongside many colleagues to the CC of yesterday and am still very unclear. It seems as if Titan (and we appreciate the FDA regulations set back) will nonetheless at current cash burn rates have to dilute shares at least 3-4 more times this fiscal year before submitting FDA final approval.
The OEM updates are interesting, but at present are high on speculation and low on specifics. Clarity must be brought into focus for the long term investor - and especially to attract additional investment.
So far this year, we have had two substantial delays, several dilutions and have just been presented with the facts of future dilutions and delays. Is it the companies' strategy to rely on speculative hype to increase the current PPS. Particularly with the first series of warrants set to expire this June, I think the company owes some clarity to long term investors on this OEM teaser. At present the market is not showing signs of being overly impressed.
It is regrettably that more questions were not asked. I for one would appreciate knowing why, if Titan is in dialogues with the big US OEM’s, as to why we are not seeking Nasdaq listings in the Us to further broaden investor base. As well, as a sign of good faith to investors who have been with the company since the beginning will Titan consider a bond issuance in lieu of further warrants?
In the event that the OEM deal does not carry with it investment funds, will the CEO as a sign of good faith purchase shares to ease investor angst. Finally, will Titan be looking to assert itself as the number two behind ISRG? It was shocking that there was barely a mention of the surgibot rejection, or a PR strategy to increase TMD profile in the marketplace.
Thank you and I look forward to your response.
Jim J.
